SAN FRANCISCO, 27/09/2022 (GLOBE NEWSWIRE) — Hagens Berman has called on Kiromic BioPharma, Inc. (NASDAQ:KIROMIC) to sell $1.5 billion. (NASDAQ:KRBP) Investors who bought Kiromic shares Submit your losses now.

school lesson: June 25, 2021 – August 13, 2021
Deadline for lead plaintiff: October 4, 2022
Visit: https://www.hbsslaw.com/investor-fraud/KRBP
Contact a lawyer now: [email protected]
844-916-0895

Kiromic BioPharma, Inc. (KRBP) Securities Class Action:

The litigation focuses on Kiromic’s statements regarding the development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1, which will allow the company to issue 8 million shares at $40 per share to investors, their secondary offering was completed on or about July 1, 2021.

Specifically, Kiromic stated that it has applications to begin human clinical trials for the two new drug candidates, known as Investigational New Drug (“IND”) applications, pending with the FDA and that the Company will within 30 days of These IND applications may begin clinical trials unless the FDA has issued a clinical lockdown.

Unbeknownst to investors, on June 16 and 17, 2021, the Company received communications from the FDA informing it that the FDA was placing the IND applications for its two candidate products on clinical hold.

On July 16, 2021, two weeks after completing the order, Kiromic announced that it had received “comments” from the FDA on its two IND applications.

Then, on August 13, 2021, the company clarified that the FDA had placed the INDs on “clinical lockdown.”

After class time, on January 27, 2022, the company’s CEO abruptly resigned.

These events drove the price of Kiromic shares down sharply.

“We are focused on investor losses and proving that Kiromic misled investors by not disclosing the FDA’s June clinical lockdown notices,” said Reed Kathrein, Hagens Berman’s partner who is responsible for the led investigation.

If you have invested in Kiromic and are experiencing significant losses or have knowledge that can help you…